A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90033, United States
San Francisco, California 94115, United States
Spartanburg, South Carolina 29303, United States
Kashiwa-shi, Chiba 277-8577, Japan
Koto-ku, Tokyo 135-8550, Japan
L'Hospitalet de Llobregat, Catalonia 08908, Spain